Market Overview:
The global infectious vaccines market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of infectious diseases, rising demand for preventive vaccines, and technological advancements in vaccine development. The global infectious vaccines market is segmented by type, application, and region. By type, the market is divided into preventive vaccines and therapeutic vaccines. The preventive vaccine segment accounted for the majority share of the global infectious vaccines market in 2017 and is projected to grow at a CAGR of 11% during the forecast period. This can be attributed to factors such as rising awareness about immunization among adults and children and increasing initiatives by governments across countries for vaccination programs.
Product Definition:
An infectious vaccine is a vaccine that protects against an infection. Infectious vaccines are important because they can help protect people from getting sick and can help prevent the spread of disease.
Preventive vaccine:
The preventive vaccine is a vaccine that prevents the occurrence of a disease rather than treating an existing condition. The prevention of diseases can be done by vaccination or natural infection, however, it is easier to do it through vaccination as there are no side effects associated with it.
Preventive vaccines have been around for quite some time; however, they were not efficiently used in most parts of the world due to lack of knowledge and fear regarding their benefits and practicality.
Therapeutic vaccine:
Therapeutic vaccine is used for the treatment of diseases caused by germs, bacteria, fungi or viruses. These are also known as biological drugs or biologics. Therapeutic vaccines can be divided into two categories: active and passive.
Application Insights:
Adults segment held the largest share of infectious vaccines market in 2017. This can be attributed to growing global awareness about immunization against a number of infectious diseases that cause mortality and morbidity. According to WHO, an estimated 10 million people die every year due to infections. Moreover, around 37 million people are hospitalized and another 69 million are treated as outpatients for these infections worldwide. In addition, according to the U.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of manufacturers, suppliers, and researchers working on infectious disease vaccines. The U.S., which is at the forefront, has witnessed several clinical trials for various types of vaccines against COVID-19 pandemic strains as well as seasonal ones such as H1N1 influenza virus and Ebola virus disease (EVD). In addition to this, increasing government initiatives coupled with high healthcare expenditure levels are some other factors contributing toward growth in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising awareness about infectious diseases among people coupled with growing target population base especially in developing countries such as India and China; hence increasing demand for preventive measures including vaccination programs against these diseases.
Growth Factors:
- Increasing incidence of infectious diseases: The global incidence of infectious diseases is increasing at a rapid pace. This is primarily due to the changing lifestyles and environmental conditions. This, in turn, is fueling the demand for effective and safe vaccines against various infections.
- Growing awareness about preventive measures: There is a growing awareness among people about the importance of preventive measures against infections. This is boosting the demand for vaccines worldwide.
- Technological advancements in vaccine development: The technological advancements in vaccine development are aiding in the development of novel and more effective vaccines against various infections. This is propelling the growth of the global infectious vaccines market significantly.
Scope Of The Report
Report Attributes
Report Details
Report Title
Infectious Vaccines Market Research Report
By Type
Preventive vaccine, Therapeutic vaccine
By Application
Adults, Pediatrics
By Companies
CSL Limited (Australia), Bavarian Nordic (Denmark), GlaxoSmithKline plc. (U.K.), Emergent Bio Solutions Inc. (U.S.), MedImmune LLC (U.S.), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Sanofi Pasteur (France), Pfizer Inc. (U.S.)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Infectious Vaccines Market Report Segments:
The global Infectious Vaccines market is segmented on the basis of:
Types
Preventive vaccine, Therapeutic vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Pediatrics
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Limited (Australia)
- Bavarian Nordic (Denmark)
- GlaxoSmithKline plc. (U.K.)
- Emergent Bio Solutions Inc. (U.S.)
- MedImmune LLC (U.S.)
- Johnson and Johnson (U.S.)
- Novartis AG (Switzerland)
- Merck and Company (U.S.)
- Sanofi Pasteur (France)
- Pfizer Inc. (U.S.)
Highlights of The Infectious Vaccines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Preventive vaccine
- Therapeutic vaccine
- By Application:
- Adults
- Pediatrics
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Infectious Vaccines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Infectious vaccines are vaccines that contain live, attenuated viruses. These viruses are weakened versions of the viruses that cause diseases in humans. The vaccine is designed to help protect people from these diseases by helping to build up immunity to the virus.
Some of the major players in the infectious vaccines market are CSL Limited (Australia), Bavarian Nordic (Denmark), GlaxoSmithKline plc. (U.K.), Emergent Bio Solutions Inc. (U.S.), MedImmune LLC (U.S.), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Sanofi Pasteur (France), Pfizer Inc. (U.S.).
The infectious vaccines market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Infectious Vaccines Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Infectious Vaccines Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Infectious Vaccines Market - Supply Chain
4.5. Global Infectious Vaccines Market Forecast
4.5.1. Infectious Vaccines Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Infectious Vaccines Market Size (000 Units) and Y-o-Y Growth
4.5.3. Infectious Vaccines Market Absolute $ Opportunity
5. Global Infectious Vaccines Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Infectious Vaccines Market Size and Volume Forecast by Type
5.3.1. Preventive vaccine
5.3.2. Therapeutic vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Infectious Vaccines Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Infectious Vaccines Market Size and Volume Forecast by Application
6.3.1. Adults
6.3.2. Pediatrics
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Infectious Vaccines Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Infectious Vaccines Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Infectious Vaccines Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Infectious Vaccines Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Infectious Vaccines Demand Share Forecast, 2019-2029
9. North America Infectious Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Infectious Vaccines Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Infectious Vaccines Market Size and Volume Forecast by Application
9.4.1. Adults
9.4.2. Pediatrics
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Infectious Vaccines Market Size and Volume Forecast by Type
9.7.1. Preventive vaccine
9.7.2. Therapeutic vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Infectious Vaccines Demand Share Forecast, 2019-2029
10. Latin America Infectious Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Infectious Vaccines Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Infectious Vaccines Market Size and Volume Forecast by Application
10.4.1. Adults
10.4.2. Pediatrics
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Infectious Vaccines Market Size and Volume Forecast by Type
10.7.1. Preventive vaccine
10.7.2. Therapeutic vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Infectious Vaccines Demand Share Forecast, 2019-2029
11. Europe Infectious Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Infectious Vaccines Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Infectious Vaccines Market Size and Volume Forecast by Application
11.4.1. Adults
11.4.2. Pediatrics
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Infectious Vaccines Market Size and Volume Forecast by Type
11.7.1. Preventive vaccine
11.7.2. Therapeutic vaccine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Prouct Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Infectious Vaccines Demand Share, 2019-2029
12. Asia Pacific Infectious Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Infectious Vaccines Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Infectious Vaccines Market Size and Volume Forecast by Application
12.4.1. Adults
12.4.2. Pediatrics
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Infectious Vaccines Market Size and Volume Forecast by Type
12.7.1. Preventive vaccine
12.7.2. Therapeutic vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Infectious Vaccines Demand Share, 2019-2029
13. Middle East & Africa Infectious Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Infectious Vaccines Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Infectious Vaccines Market Size and Volume Forecast by Application
13.4.1. Adults
13.4.2. Pediatrics
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Infectious Vaccines Market Size and Volume Forecast by Type
13.7.1. Preventive vaccine
13.7.2. Therapeutic vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Infectious Vaccines Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Infectious Vaccines Market: Market Share Analysis
14.2. Infectious Vaccines Distributors and Customers
14.3. Infectious Vaccines Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. CSL Limited (Australia)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bavarian Nordic (Denmark)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline plc. (U.K.)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Emergent Bio Solutions Inc. (U.S.)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. MedImmune LLC (U.S.)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Johnson and Johnson (U.S.)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis AG (Switzerland)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Merck and Company (U.S.)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Sanofi Pasteur (France)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pfizer Inc. (U.S.)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
